The Novo Nordisk Inc. (NNI) Investigator Sponsored Studies (ISS) Program will accept protocols within our current areas of interest (AOI) as noted below. This is a competitive process. Incomplete submissions or protocols that are not within the scope of these AOIs/have low relevance to the thereaputic area may be rejected without further review. Submissions will be reviewed by the Novo Nordisk teams on both the US (NNI) and Global level. Decisions will be made based on scientific merit and strategic fit. Please review the submission requirements and abide by the timelines as outlined below.  The program requests that investigators specify how they will support enrollment of diverse populations in the study.

Please note that all new clinical ISS applications requesting oral Semaglutide are currently on pause and not being accepted.

Women’s health

  • Menopause-related
  • Polycystic Ovary Syndrome (PCOS)

Obstructive Sleep apnea

Weight loss maintenance

  • Dose flexibility (e.g., drug holiday, time on/off)

Drug switching (between anti-obesity medications)

Effects of intentional weight loss on body composition related to:

  • Muscle mass, function and quality
  • Bone health

Effects of GLP1 on gastric emptying

Cancer with 2.4mg primary and secondary prevention

Addictive disorders

Obesity subpopulations:

  • Populations disproportionately affected by obesity


Obesity-related comorbidities including but not limited to:

  • Cancer (e.g., pathophysiology, outcomes, risk, remission etc.)
  • Atherosclerotic cardiovascular disease (ASCVD)

 

Obesity in relation to:

  • Primary prevention of disease with intentional weight loss
  • Obesity pathophysiology (e.g., metabolic adaptation) and body composition


Other:

  • Protocols not in conflict or redundant with NN research/scientific commitment in the thereaputic area

 

  • Studies that overlap with completed, ongoing or planned research

  • Protocol
  • Detailed line-item budget
  • Principal Investigator CV
  • Active medical license (e.g., if requesting study drug)
  • Conflict of Interest form

Open: March 17, 2025

Closes: June 1, 2025 @ 11:59pm ET

August/September 2025